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Abstract
Background: Serum-mediated phagocytosis of antibody- and complement-opsonized necrotic cell material (NCM)
by polymorphonuclear leukocytes can be quantified by using a flow cytometry–based assay. The phagocytosis of
necrotic cell material (PNC) assay parallels the well-known lupus erythematosus cell test. In this study, we aimed to
investigate the diagnostic accuracy of the assay and the relationship with clinical manifestations and disease activity
in systemic lupus erythematosus (SLE).
Methods: The diagnostic accuracy for SLE diagnosis of the PNC assay was studied by cross-sectional assessment of
blood samples from 148 healthy control subjects and a multicenter rheumatic group (MRG) of 529 patients with
different rheumatic symptoms. A cohort of 69 patients with an established SLE diagnosis (SLE cohort) underwent
longitudinal clinical and laboratory follow-up for analysis of the temporal relationships between PNC positivity and
specific clinical manifestations.
Results: In 35 of 529 MRG patients, 13 of whom had SLE, the PNC assay result was positive. Combined positivity of
the PNC assay and anti–double-stranded DNA antibodies increased specificity and positive predictive value for SLE
diagnosis to 0.99 and 0.67, respectively. In the longitudinal study, 42 of 69 SLE cohort patients had positive results
in the PNC assay at least once. PNC assay positivity was associated with current hematological manifestations
and could predict mucocutaneous manifestations. When combined with hypocomplementemia, PNC positivity
preceded increased Systemic Lupus Erythematosus Disease Activity Index 2000 score, glomerulonephritis, and alopecia.
Conclusions: Serum-mediated PNC by polymorphonuclear leukocytes is commonly but not exclusively seen in
patients with SLE. The PNC assay may be used in follow-up of patients with SLE and, especially in combination with
other routinely assessed laboratory tests, may help to predict flares and different clinical manifestations, including
glomerulonephritis. Our results encourage further development of the PNC assay as a complementary laboratory tool
in management of patients with SLE.
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Background
Systemic lupus erythematosus (SLE) is an autoimmune
syndrome of unknown etiology, with a complex interplay
between genetic and environmental factors [1, 2] and be-
tween the innate and the adaptive immune systems [3].
The disease commonly affects women of childbearing
age and is characterized by chronic inflammation in
several different organ systems with potentially life-
threatening outcomes. Many clinical manifestations of
SLE are caused by immune complex deposition in target
organ and subsequent inflammation caused by comple-
ment activation and infiltration of immune cells. Among
the different cells involved in the pathogenesis of SLE,
the crucial role played by polymorphonuclear leukocytes
(PMNs) has recently been emphasized [4–12]. The
immune complexes mostly contain nuclear material able
to stimulate immune cells through Toll-like receptor 7
(TLR7) and TLR9, and are formed upon binding of auto-
antibodies to different antigens, often remnants of cells
dying due to impaired clearance of apoptotic cells [8, 13].
Although SLE classification criteria have been formu-
lated and periodically updated [14–17], these criteria are
constructed to classify patient materials for research pur-
poses and are not diagnostic criteria meant to be used in
clinical practice [18]. Furthermore, there is a great need
for novel diagnostic and prognostic tools to complement
the ones already in use, including assessment of anti-
bodies against double-stranded DNA (dsDNA) and his-
tone proteins, as well as consumption of components of
the classical pathway of the complement system. The
first laboratory test proposed as a diagnostic tool for
SLE was the lupus erythematosus (LE) cell, described in
1948 as a specific finding in bone marrow leukocytes in
patients affected by SLE [19]. Further studies have
shown that LE cells consist of mature PMNs in which
the nucleus has been dislocated to the periphery of the
cell after engulfment of antibody- and complement-
opsonized nuclear material [20, 21]. The presence of LE
cells was included in the list of the classification criteria
for SLE [14, 17] and related to more severe clinical man-
ifestations [22, 23]. The LE cell was rarely observed in
other rheumatic [24] and non-rheumatic disorders [25], but
published data on the diagnostic accuracy of the LE cell test
in unselected patients are still missing [22, 26, 27]. Previous
studies showed that the phenomenon is dependent on
anti-dsDNA antibodies [21] and anti-histone antibodies,
in particular anti-histone H1 antibodies [28]. Because of
its complexity, the assessment of LE cells by light micros-
copy was abandoned as a routine test in favor of other
diagnostic tools, including anti-dsDNA antibody analysis.
More recently, a flow cytometry–based assay—the
phagocytosis of necrotic cells (PNC) assay—was devel-
oped as an in vitro assessment and quantification of LE
cells in patients with suspected SLE [29], but its use in
clinical practice has never been validated. In a previous
study [30], our group demonstrated that the outcome of
the PNC assay is often positive in patients with SLE with
increased disease activity. The phagocytosis seems to be
associated with oxidative burst activity that is mediated
by Fc γ-receptor IIA (FcγRIIA), FcγRIIIB, and comple-
ment receptor type 1 in combination. The phagocytosis
is more efficient in the presence of high levels of dif-
ferent anti-histone antibodies and when the classical
pathway of the complement system is functional and
active [30].
In this study, we show that the PNC assay, by detecting
serum-mediated phagocytosis of necrotic cell material
(NCM), may be used as a tool in the process of diagnosing
SLE. Furthermore, we found that the outcome of the PNC
assay was related to clinical manifestations and, in com-
bination with other established biomarkers, with disease
activity.
Methods
Assay for phagocytosis of necrotic cell material assay
Serum-mediated phagocytosis of NCM by PMNs was
performed as described by Böhm [29], with some modi-
fications [30]. Briefly, PMNs and peripheral blood mono-
nuclear cells (PBMCs) were isolated from heparinized
blood using Polymorphprep™ (Axis-Shield Poc AS, Oslo,
Norway) according to the manufacturer’s protocol. To
induce cell death, PBMCs were incubated for 10 minutes
at 70 °C, and the NCM was stained with propidium
iodide (PI; BD Biosciences, San Diego, CA, USA). PMNs
were stained with anti-CD66 fluorescein isothiocyanate
antibodies (Dako A/S, Glostrup, Denmark).
For autoantibody binding and complement activation,
PI-labeled NCM (4.5 × 105 cells) was incubated with 30 μl
of undiluted serum at room temperature for 20 minutes,
followed by addition of PMNs isolated from healthy in-
dividuals (0.3 × 106 cells in a total volume of 300 μl) for
another incubation at 37 °C for 15 minutes. Cells were
washed with phosphate-buffered saline, pH 7.2, con-
taining 0.1 % human serum albumin (Sigma-Aldrich,
St. Louis, MO, USA) before analysis by flow cytometry.
PMNs were identified on the basis of forward and side
scatter properties and by computerized gating (Fig. 1).
Phagocytosis was calculated from the percentage of
cells positive for both CD66 and PI (percentage of
CD66+PI+ PMNs). A sample was considered positive if
the PNC value was higher than the mean value ob-
tained in 148 healthy individuals added with 3 standard
deviations. All the measurements performed in the SLE
cohort were included to analyze the relationships be-
tween PNC results and SLE-related clinical manifesta-
tions. Only the result obtained in the first measurement
in every patient in the SLE cohort was taken into ac-
count for the comparison with the outcome of PNC
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assay obtained in healthy individuals and in patients
from the multicenter rheumatic group (MRG).
Other laboratory tests
In the SLE cohort, routine laboratory tests were used for
the longitudinal measurement of all the variables needed
to assess disease activity according to the Systemic Lupus
Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
[31], including the complement components C1q, C3, and
C4. A semi-quantitative assessment of anti-nuclear anti-
bodies (ANA) and anti-dsDNA antibodies [Crithidia
luciliae immunofluorescence test (CLIFT)] was performed
with immunofluorescence tests, using as substrates Hep-2
cells and Crithidia luciliae, respectively (Euroimmun,
Lübeck, Germany). Enzyme-linked immunosorbent assay
measurement of antibodies against a mixture of histone
proteins was performed as previously described [30]. Only
ANA and CLIFT were assessed cross-sectionally in the
MRG patients, by the routinely used method in the re-
spective participating center, as described elsewhere [32].
Patients and controls
Demographics of the 148 healthy volunteers and 529
MRG patients are presented in Fig. 2. In three different
centers [Copenhagen in Denmark (138 patients), Lund
in Sweden (269 patients), and Tromsø in Norway (122
patients)], MRG patients were recruited and grouped
according to initial clinical diagnoses, as previously
described [32]. In brief, patients with recent onset of any
suspected rheumatic disease and referred for the first
time to rheumatologists were recruited for clinical
assessment and analysis of ANA and anti-dsDNA anti-
bodies. The cross-sectional performance of the PNC
assay in these patients was intended to obtain reference
values of the test in rheumatic patients and to evaluate
its diagnostic value in a realistic clinical situation, such
as in patients with early onset of rheumatic manifesta-
tions, when the diagnosis is still unknown. We focused
on the outcome of the test in the subgroup of patients
later diagnosed with SLE, in comparison with other
groups of rheumatic diseases. The final diagnoses were
formulated by the clinician at the participating center on
the basis of the clinical features, regardless of the fulfill-
ment of classification criteria, after a median follow-up
period of 4.7 years (Table 1).
To study the temporal associations between the out-
come of the PNC assay and SLE-related clinical pheno-
types, we performed the PNC assay repeatedly over time
in a cohort of 69 patients (Fig. 2) affected by SLE who
fulfilled the American College of Rheumatology (ACR)
1982 classification criteria for SLE [17]. These patients
participated in a prospective follow-up program at
the Rheumatology Clinic, University Hospital, Lund,
Sweden, with the general purpose of improving care of
patients with SLE and to identify clinical and laboratory
variables that could be considered as markers or predic-
tors of complications and exacerbations of the disease.
They were followed longitudinally with a median of 14
(2–43) visits periodically scheduled every 60 ± 20 days. An
extensive set of clinical and laboratory variables were reg-
istered in a database tailored for the study. Serum samples
were collected before and after the date of the clinical
assessment when needed.
Demographics, clinical features, and prevalence of mani-
festations included in the ACR classification criteria in
SLE cohort are summarized in Table 2. Disease activity
was assessed every time, using the SLEDAI-2K [31]. For
the assessment of relationships with outcomes of the PNC
assay in combination with other biomarkers, a modified
version of the SLEDAI-2K was used, excluding any score
given for low levels of complement factors and/or anti-
dsDNA antibodies.
Fig. 1 Flow cytometric analysis results. a Forward scatter analysis (FSC-A) and side scatter analysis (SSC-A) of polymorphonuclear cells (neutrophils
in gate P5) in a healthy control. b Negative outcome of phagocytosis of necrotic cell material (PNC) assay in a healthy control, where only 1.7 %
of gated neutrophils are positive for propidium iodide (PI) and CD66. c Positive outcome of PNC assay in a patient affected by systemic lupus
erythematosus, where 38.9 % of gated neutrophils are positive for PI and CD66
Compagno et al. Arthritis Research & Therapy  (2016) 18:44 Page 3 of 11
Fig. 2 Demographics and results of phagocytosis of necrotic cell material (PNC) assay in all the study participants. Age of the patients and percentage
of double-positive polymorphonuclear cells (PI+CD66+ PMNs) are expressed as median values (range in brackets). The percentage of double-positive
PNC results is significantly higher in patients affected by SLE compared with healthy controls and non-SLE patients in the multicenter rheumatic group.
PI propidium iodide, SLE systemic lupus erythematosus
Table 1 Positive outcome of PNC assay and CLIFT in MRG patients
Diagnosis PNC+ (%) CLIFT+ (%) PNC+CLIFT+ (%) Total (%)
Arthralgia [%] 2 (5.7) [5.9] 0 0 34 (6.4) [100]
Connective tissue disease [%] 3 (8.6) [5.6] 7 (15.9) [13] 2 (13.3) [3.7] 54 (10.2) [100]
Dermatological disorder [%] 0 0 0 17 (3.2) [100]
Inflammatory joint disease [%] 3 (8.6) [2.7] 8 (18.2) [7.1] 2 (13.3) [1.8] 112 (21.2) [100]
Osteoarthritis [%] 6 (17.1) [10.2] 0 0 59 (11.2) [100]
Non-rheumatic disease [%] 6 (17.1) [5] 6 (13.6) [5] 1 (6.7) [0.8] 120 (22.7) [100]
Soft tissue rheumatism [%] 1 (2.9) [4] 0 0 25 (4.7) [100]
Systemic inflammatory disease [%] 1 (2.9) [4.2] 2 (4.5) [8.3] 0 24 (4.5) [100]
Unspecified [%] 0 0 0 19 (3.6) [100]
SLE [%] 13 (37.1) [20] 21 (47.7) [32.3] 10 (66.7) [15.4] 65 (12.3) [100]
Total 35 (100) 44 (100) 15 (100) 529 (100)
CLIFT Crithidia luciliae immunofluorescence test, PNC phagocytosis of necrotic cell material, SLE systemic lupus erythematosus
The different subsets of patients are grouped on the basis of final diagnosis recorded after a median of 4.7 years, as described elsewhere [32]. The percentage of
positive laboratory tests is reported in round brackets; the percentage of positive patients in the different subsets is reported in square brackets
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Ethics
All subjects entered the study after giving informed
written consent, according to the Helsinki declaration.
The study was performed according to the approval by
the local ethical committees of the participating centers
in Lund, Sweden (Research Ethics Committee, Medical
Faculty, Lund University); Tromsø, Norway (Regional
Committee for Medical and Health Research Ethics -
REC North); and Copenhagen, Denmark (research ethics
committees for Copenhagen and Frederiksberg).
Statistical analysis
Descriptive statistics were calculated, and the Kruskal-
Wallis test was used for analysis of non-parametric data.
Sensitivity, specificity, positive predictive value (PPV),
likelihood ratio for positive (LR+) and negative (LR-) re-
sult of PNC assay, CLIFT and the combination of the two
assays (PNC+CLIFT+) were calculated to assess their
diagnostic accuracy for SLE diagnosis in MRG patients.
Moreover, receiver operating characteristic (ROC) curves
were plotted and area under the curve (AUC) were calcu-
lated for PNC assay, CLIFT, the combination of the two
assays (PNC+CLIFT+) and ANA. Temporal associations
between positive outcomes of PNC assays and relevant
clinical phenotypes were evaluated with a generalized lin-
ear mixed-effects model (PROC GENMOD). Odds ratios
(ORs), 95 % confidence intervals (CIs), and statistical sig-
nificance levels (p values) were calculated. A p value ≤0.05
defined statistical significance. SAS 9.3 (SAS Institute,
Cary, NC, USA) and IBM SPSS Statistics 20.0 (IBM,
Armonk, NY, USA) software was used for all statistical
analyses. Only visits within intervals of 60 ± 20 days were
considered for temporal associations.
Results
Positivity in PNC assays is specific but not exclusively
found in patients with SLE. To assess its diagnostic ac-
curacy for SLE diagnosis, the PNC assay was performed
in the 529 MRG patients. The outcomes of PNC assays
in MRG patients are summarized in Table 1. The PNC
assay was positive in 35 MRG patients (6.6 %) with
recent onset of any rheumatic symptoms. Among these
patients, the most common clinical diagnosis was SLE
(13 cases), resulting in a sensitivity of the test at 0.20,
specificity of the test at 0.95, and PPV of the test for SLE
diagnosis at 0.37. Other, less common diagnoses in
PNC-positive MRG patients were arthralgia (two cases,
5.9 % of MRG patients affected by arthralgia and 5.7 %
of PNC-positive patients), osteoarthritis (six cases,
10.2 % of MRG patients affected by osteoarthritis and
17.1 % of PNC-positive patients), inflammatory joint dis-
ease (three cases, 2.7 % of MRG patients affected by in-
flammatory joint disease and 8.6 % of PNC-positive
patients), non-rheumatic disease (six cases, 5 % of MRG
patients affected by non-rheumatic disease and 17.1 % of
PNC-positive patients), connective tissue disease (three
cases, 5.6 % of MRG patients affected by connective tissue
disease and 8.6 % of PNC-positive patients), systemic in-
flammatory disease (one case, 4.2 % of MRG patients af-
fected by systemic inflammatory disease and 2.9 % of
PNC-positive patients), and soft tissue rheumatism (one
case, 4 % of MRG patients affected by soft tissue rheuma-
tism and 2.9 % of PNC-positive patients). In the subgroup
of 44 anti-dsDNA–positive MRG patients, 15 (34.1 %) had
a positive PNC test result. Among them, 10 had SLE, 2
had a connective tissue disease, 2 had an inflammatory
joint disease, and 1 had a non-rheumatic disease. The
positivity of CLIFT alone resulted in a sensitivity at 0.32,
specificity at 0.95, and PPV at 0.48. The combined
Table 2 Demographics, clinical characteristics, and outcomes of
PNC assay in 69 patients with SLE (SLE cohort)
Characteristics Data
Age, yr
Mean (SD) 41.4 (13.7)
Median (range) 39.2 (18–76)
Female sex, n (%) 63 (91.3)
Disease duration, yr, median (range) 7.5 (0–41)
Follow-up duration, d, median (range) 778 (139–1792)
Corticosteroid treatment, n (%) 33 (47.8)
Prednisolone equivalent, average dose last 2 mo,
median (range)
10 (1–60) mg/d
Antimalarial treatment 46 (66.7)
Hydroxychloroquine, average dose last 2 mo,
median (range)
200 (46.6–400) mg/d
Immunomodulatory treatment, n (%) 37 (53.6)
ACR classification criteria n (%)
Malar rash 46 (67 %)
Discoid rash 18 (26 %)
Photosensitivity 42 (61 %)
Oral ulcer 16 (23 %)
Arthritis 55 (80 %)
Serositis 35 (51 %)
Glomerulonephritis 35 (51 %)
Hematologic disorder 38 (55 %)
Neurologic disorder 3 (4 %)
Immunologic disorder 53 (77 %)
ANA positivity 69 (100 %)
Outcome of PNC assay, % CD66+PI+ PMNs
Mean (SD) 7.3 (9.0)
Median (range) 3.4 (0.8–49.9)
ACR American College of Rheumatology, ANA anti-nuclear antibodies;
SD standard deviation, CD66+PI+ PMNs double-stained polymorphonuclear
cells, PI propidium iodide, PNC phagocytosis of necrotic cell material
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positivity of CLIFT and the PNC assay increased the speci-
ficity to 0.99 and the PPV to 0.67 in patients with SLE
(Table 3).
Overall, the positive outcomes of PNC assays were
seen mostly in patients with SLE. The percentages of
PNC-positive patients in the different subgroups and in
healthy individuals are reported in Fig. 3.
Area under the ROC curve analysis plotting the
diagnostic accuracy for SLE of PNC assay and its
combination with CLIFT, in comparison with ANA and
CLIFT alone, is shown in Fig. 4 and Table 4. ANA and
CLIFT had the best AUC (0.7 and 0.64, respectively), sug-
gesting a sharper and more immediate diagnostic role
than PNC assay for SLE, in patients with recent onset of
rheumatic symptoms.
Relationship between PNC positivity over time and
clinical manifestations in patients with SLE
Significant differences were found in the prevalence of
clinical manifestations in patients with SLE, grouped on
the basis of the outcome of PNC assay over time
(Table 5). On one hand, 12 patients with SLE had per-
sistent PNC positivity during the entire follow-up period
on the basis of 166 total assessments. On the other
hand, 31 patients with SLE had persistently negative
PNC assay results in a total of 475 assessments. The
remaining 459 assessments in 26 patients with SLE dis-
played variable PNC results over time.
Glomerulonephritis was significantly more prevalent
among patients with persistent PNC positivity, whereas
arthritis was much more prevalent among those with
persistently negative test results. Alopecia, mucocu-
taneous features, and increased SLEDAI-2K scores were
Table 3 Diagnostic accuracy for SLE of the PNC assay, CLIFT,
and their combined positivity in MRG patients
PNC+ CLIFT+ PNC+CLIFT+
Sensitivity
(95 % CI)
0.20 (0.12–0.37) 0.32 (0.22–0.44) 0.15 (0.09–0.26)
Specificity
(95 % CI)
0.95 (0.93–0.97) 0.95 (0.93–0.97) 0.99 (0.97–0.99)
PPV (95 % CI) 0.37 (0.23–0.54) 0.48 (0.34–0.62) 0.67 (0.42–0.85)
LR+ (95 % CI) 4.22 (2.24–7.96) 6.52 (3.83–11.10) 14.28 (5.04–40.46)
LR− (95 % CI) 0.84 (0.74–0.95) 0.71 (0.60–0.84) 0.86 (0.77–0.95)
CI confidence interval, PPV positive predictive value, LR+ likelihood ratio for
positive result, LR− likelihood ratio for negative result, CLIFT Crithidia luciliae
immunofluorescence test, PNC phagocytosis of necrotic cell material,
MRG multicenter rheumatic group, SLE systemic lupus erythematosus
Fig. 3 Percentage of multicenter rheumatic group (MRG) patients and healthy controls with positive outcomes of phagocytosis of necrotic cell
material (PNC) assays. Within the subgroups of patients with systemic lupus erythematosus (SLE), the percentage of patients with positive PNC
assay results was significantly higher than in other subgroups of patients and in healthy controls. **Strongly significant difference compared with
other subsets of patients (p < 0.01). *Significant difference compared with other subsets of patients (p < 0.05)
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more prevalent in patients with persistent PNC posi-
tivity, but the difference was not statistically significant
compared with the patients with consistently negative
PNC results.
Temporal relationships between PNC positivity and
occurrence of clinical manifestations
In the SLE cohort from Lund, the PNC assay showed a
significant correlation (p ≤ 0.05) with different clinical
manifestations. In particular, a positive PNC test result
was associated with active hematologic features such as
leukopenia and thrombocytopenia (OR 7.67, 95 % CI
2.98–19.74). Positivity in the PNC assay was able to
predict mucocutaneous manifestations within the next
60 ± 20 days (OR 1.68, 95 % CI 1.15–2.46), whereas it
displayed an inverse association with future flare of
active arthritis (OR 0.36, 95 % CI 0.16–0.82). No
significant temporal correlations between PNC assay
outcomes and increased SLEDAI-2K scores were found
(Table 6).
Combination of PNC assay with other laboratory tests
correlates with clinical manifestations
The PNC assay relies on the presence of autoantibodies,
in particular antibodies directed against histone proteins
and dsDNA, as well as an intact classical pathway of the
complement system. We therefore wanted to analyze the
relationships between different clinical manifestations
and positive PNC assay results in combination with the
presence of antibodies against dsDNA or histones or
with low levels of complement components C1q, C3,
and C4.
An isolated presence of anti-dsDNA antibodies in our
SLE cohort had significant associations with glome-
rulonephritis, mucocutaneous manifestations, alopecia,
and increased SLEDAI-2K score (data not shown). The
presence of anti-dsDNA antibodies together with a posi-
tive PNC assay result showed no association with any
current or upcoming clinical manifestation.
Positivity of anti-histone antibodies alone was associ-
ated with active glomerulonephritis and mucocutaneous
manifestations. Anti-histone antibodies in combination
with a positive PNC test result could predict future flare
of mucocutaneous manifestations within 2 months
(OR 2.33, 95 % CI 1.21–4.78, p = 0.011).
Fig. 4 Area under the ROC curve analysis showing diagnostic accuracy of different tests for systemic lupus erythematosus in multicenter rheumatic
group patients. ANA anti-nuclear antibodies, CLIFT Crithidia luciliae immunofluorescence test, PNC phagocytosis of necrotic cell material
Table 4 Positive results for PNC assay, CLIFT, ANA, and
combination of PNC and CLIFT
Test result Area under
the curve
95 % confidence interval
Lower bound Upper bound
PNC+ 0.58 0.50 0.66
CLIFT+ 0.64 0.56 0.72
ANA+ 0.70 0.65 0.76
PNC+CLIFT+ 0.57 0.49 0.65
ANA anti-nuclear antibodies, CLIFT Crithidia luciliae immunofluorescence test,
PNC phagocytosis of necrotic cell material
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Low levels of C1q were associated with concomitant
glomerulonephritis. Low levels of C3 (with or without
concomitant low levels of C4) were associated with
mucocutaneous manifestations (e.g., rash, oral ulcers).
The combination of hypocomplementemia with a posi-
tive PNC assay showed a strong relationship with active
glomerulonephritis, alopecia, and increased modified
SLEDAI-2K score. In particular, a positive PNC assay
result in combination with a low level of C3 was associ-
ated with increased SLEDAI-2K score (OR 2.34, 95 % CI
1.29–4.24, p = 0.005), predicted flare of glomeruloneph-
ritis (OR 2.29, 95 % CI 1.12–4.67, p = 0.023), and alo-
pecia (OR 5.64, 95 % CI 1.49–21.32, p = 0.011) within
the next 2 months. Low levels of C1q in combination
with positive PNC assay results were associated with
present (OR 1.74, 95 % CI 1.01–2.99, p = 0.045) and
upcoming (OR 2.12, 95 % CI 1.03–4.37, p = 0.042) ac-
tive glomerulonephritis.
Discussion
Our data show that the PNC assay might partially improve
the diagnostic accuracy of anti-dsDNA antibodies for SLE
in patients with a recent onset of rheumatic symptoms. In
patients with established SLE, its positive outcome was
strongly correlated with ongoing hematological features
such as leukopenia and thrombocytopenia. Furthermore,
by itself and/or in combination with other laboratory ana-
lyses, the PNC assay was able to predict upcoming disease
manifestations (within 2 months) in patients with SLE,
including mucocutaneous features, alopecia, and glomer-
ulonephritis. Altogether, the results of our investigation
support the use of the PNC assay in clinical praxis to
sharpen the diagnostics in undiagnosed patients and to
improve the evaluation of prognosis in patients with SLE.
Early identification of patients with negative prognostic
factors, because of prediction of worsened outcome,
should lead to earlier adjustment of their management
and to overall decreased disease activity.
We started the investigation by assessing reference
values of a PNC assay in apparently healthy individuals.
The obtained reference values were evaluated in a
Scandinavian group of patients with recent onset of any
rheumatic symptoms. By comparing patients with SLE
with patients affected by other disorders, we could dem-
onstrate that SLE is by far the most common diagnosis
related to a positive outcome of PNC assay, especially in
anti-dsDNA antibody–positive patients (Table 1). One
reason for a positive PNC assay result in patients with
no SLE diagnosis and absence of detectable anti-dsDNA
antibodies may be the presence in serum of autoanti-
bodies against other parts of the NCM, including his-
tones or nucleosomes.
In a realistic diagnostic setting, the physician is initially
unaware of the correct diagnosis in patients with recent
onset of rheumatic symptoms and the use of reliable
laboratory tools plays an important diagnostic role. It is
important to emphasize that the PPV for SLE after a
cross-sectional analysis of the PNC assay is low. Other
clinical diagnoses can be found in patients with a
positive test, more frequently in anti-dsDNA–negative
patients. We have previously reported that the PPV for
SLE after a cross-sectional analysis of CLIFT alone in a
similar population was 0.46 [32]. Nonetheless, the com-
bined positivity of CLIFT and PNC assay in the present
Table 5 Most frequent clinical manifestations in patients
with SLE
Clinical
manifestation
Always positive
PNC (n = 12
patients, 166
assessments)
Always negative
PNC (n = 31
patients, 475
assessments)
Variable
PNC (n = 26
patients, 459
assessments)
Glomerulonephritis 31.9 % 10.5 %a 6.5 %a
Arthritis 1.8 %b 16.6 % 6.1 %a,b
Mucocutaneous 24.7 % 21.3 % 13.9 %a,b
Alopecia 10.8 % 7.8 % 7.2 %
Hematologic 3.0 %c 1.1 %c 7.0 %b
SLEDAI-2K >1 57.8 % 48.8 % 44.7 %a,b
SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000
aSignificant difference (p ≤ 0.05) compared with “Always positive PNC”
bSignificant difference (p ≤ 0.05) compared with “Always negative PNC”
cSignificant difference (p ≤ 0.05) compared with “Variable PNC”
The 69 patients are grouped depending on the outcome of PNC assay
(positive or negative) over time
Table 6 Temporal associations between occurrence of the most frequent clinical manifestations and positive PNC assay results
Clinical manifestation Occurrence of clinical manifestation
Same time as positive PNC After positive PNC
OR 95 % CI p Value OR 95 % CI p Value
Glomerulonephritis 1.48 0.95–2.31 0.080 1.41 0.80–2.50 0.233
Arthritis 0.72 0.39–1.34 0.303 0.36 0.16–0.82 0.015
Mucocutaneous 1.36 0.94–1.97 0.105 1.68 1.15–2.46 0.007
Alopecia 0.87 0.47–1.60 0.657 1.37 0.81–2.32 0.239
Hematological features 7.67 2.98–19.74 <0.001 0.59 0.28–1.26 0.173
SLEDAI-2K >0 1.27 0.86–1.88 0.222 1.24 0.83–1.85 0.288
OR odds ratio, CI confidence interval, PNC phagocytosis of necrotic cell material, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000
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study resulted in a PPV of 0.67, suggesting an additive
diagnostic role of the PNC assay in patients affected by
SLE. Furthermore, although our study had a median
follow-up of 4.7 years, it is possible that some of the in-
dividuals with positive PNC assay will still develop SLE
in the future with or without any other overlapping
rheumatic disease.
The second main aim of the present study was to in-
vestigate any potential predictive value of the PNC assay
with regard to SLE-related clinical manifestations. In
particular, we wanted to study whether the positive
outcome of the test (alone or in combination with con-
comitant presence of anti-histone and/or anti-dsDNA
antibodies and/or hypocomplementemia) coincides with
or predicts the occurrence of any relevant clinical mani-
festations or changes in disease activity.
On one hand, the occurrence of glomerulonephritis
was much more frequent in patients with SLE with
persistent positive outcome of PNC assay, compared
with those where the outcome was variable over time or
always negative (Table 5). On the other hand, the occur-
rence of arthritis was much more frequent in patients
with persistently negative PNC assay outcomes (Table 5).
Although patients with PNC positivity had an increased
SLEDAI-2K score, we could not show any significant
association over time of the PNC assay with SLE disease
activity. However, in combination with low complement
levels, PNC positivity could predict upcoming flare, in
particular active glomerulonephritis. The additive effect
of low complement levels may be counterintuitive, con-
sidering the essential role of complements in the PNC
assay [30]. However, low complement levels are often
sufficient to activate the classical pathway of comple-
ments [33] and may also be a sign of ongoing immune
complex–mediated disease, such as the ones detected in
the PNC assay. Interestingly, positivity in the PNC assay
also displayed an inverse association with development
of arthritis, a clinical manifestation with much higher
prevalence in patients with SLE with consistently nega-
tive PNC assay outcomes. It strongly suggests and sup-
ports the hypothesis that neutrophil abnormalities are
related to a distinct lupus phenotype associated with se-
vere manifestations, including hematological features
and glomerulonephritis, similar to what has been de-
scribed previously [30].
The PNC assay may help the physician to distinguish
between different phenotypes in patients with SLE. The
test displayed a highly significant correlation with con-
comitant hematological manifestations such as leukopenia
and thrombocytopenia. It may suggest a potential role of
the PNC assay as a marker for these relevant features. We
do not have sufficient data at the moment to establish
whether the hematological manifestations in our SLE
cohort were related to active SLE or other causes, such as
concomitant treatment with cytotoxic drugs, infections, or
other. If our results are confirmed, the PNC assay could
be a valid test that would provide the clinician with im-
portant information on whether the hematological mani-
festations are SLE-related. SLE-related hematological
manifestations may require higher doses of immunosup-
pressive treatment, whereas a dose reduction or interrup-
tion of the treatment is often recommended whenever
leukopenia and thrombocytopenia are supposed to be side
effects of the treatment itself. To our knowledge, no other
validated tests used in the management of patients with
SLE are good enough to obtain the same information.
Limitations of the present investigation are mostly due
to the cross-sectional analysis of the PNC assay in MRG
patients and healthy individuals. Moreover, the labora-
tory analysis in MRG patients was limited to ANA and
anti-dsDNA antibodies, besides the PNC assay. We have
no data at the moment to discern anything about the
variation over time of the outcome of the PNC test in
healthy individuals or in patients without SLE with re-
cent onset of rheumatic symptoms. This is an important
aspect to analyze in future studies because the longitu-
dinal analysis in the SLE cohort showed that the out-
come of the PNC assay may influence the prevalence of
crucial clinical features. Data that verify how anti-
histone antibodies and the classical pathway of the com-
plement system may influence the outcome of the PNC
assay in these patients should also be included.
Recent discoveries, including the formation of neutro-
phil extracellular traps (NETs), a neutrophil cell death
process in which several key autoantigens (including
dsDNA and histones) are extruded from the neutrophil
[34], as well as the identification of spontaneously NET-
forming low-density granulocytes, an immature inflamma-
tory neutrophil subset highly enriched in inflammatory
conditions such as SLE [9, 10], have highlighted neu-
trophils as important immune cells in SLE pathogenesis
[9, 11, 35]. Although NETs are cleared silently by macro-
phages in healthy individuals [36], patients with SLE have
impaired clearance of NETs due to the presence of auto-
antibodies as well as decreased DNase I activity [6, 12, 37],
enabling recognition of NETs by plasmacytoid dendritic
cells and induction of type I interferons, key cytokines in
SLE pathogenesis [38]. However, the clinical utility of
assessing neutrophil function in the diagnosis and progno-
sis of patients with SLE has not been addressed. In the
present study, we evaluated the diagnostic and prognostic
value of the PNC assay, a functional test used to assess the
ability of PMNs to engulf autoantibody- and complement-
opsonized cell debris.
Conclusions
Assessment of serum-mediated phagocytosis of NCM by
PMNs as determined by the PNC assay may be
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considered a useful supplementary laboratory tool in the
management of patients affected by SLE. Either alone or
in combination with other laboratory tests, the PNC
assay may provide the clinician with additional informa-
tion in the diagnostic process and in assessing current
and, more importantly, risk for future disease activity, as
well as occurrence of clinical manifestations and pheno-
types, such as glomerulonephritis, hematological, and
mucocutaneous manifestations. Long-term longitudinal
assessment of PNC assay in larger cohorts of patients
with SLE is needed to validate the test as a relevant tool
in the management of the disease.
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